No.2
|
|
|
- こうだい すわ
- 7 years ago
- Views:
Transcription
1 Views and Actions MR MR OPIR OPIR Office of Pharmaceutical Industry Research
2 Points of Views GCP GCP GCP GCP
3 CRC CRC CRC CRC CRC IRB CRC CRC CRC patientoriented patientoriented IT CRC
4 patient oriented CRC
5 Points of Views HMO PBM McCainSchumer
6 QOL QOL Health Maintenance OrganizationsHMO Pharmacy Benefit ManagementPBM No
7 Points of Views MR MR EBMEvidence Based Medecine MR MR MR MR
8 MR MR MR MR MR MR MR MR MR MR MR MR MR CSOcontract sales oraganization MR MR PMS MR MR
9 MRPMS A B C D MR MR MR PMS MR MR MR MR MRPMS MR MR PMS MR PMS BC A MR MR
10 MR PMS MR MR PMS PMS PMS MR MR PMS A B C D MR MR MR MR MR MR PMS PMS
11 PH PH PH
12
13 No
14
15 ROEROE ROE ROE ROE
16 ROE Merck Pfizr J & J BMS Pharmacia Abbott AHP Eli Lilly ScheringP Amgen ROE
17 MSA No No JP
18 JpnPharmacoedpiemiol June: No No No No
19 MR MR IT
20 TEL FAX
第１章 製薬産業を取り巻く環境変化
2015 2007 5 1 2 2015 2007 5 103-0023 3-4-1 5F TEL : 03-5200-2681 FAX : 03-5200-2684 E-mail : sasabayashi-opir@jpma.or.jp URL : http://www.jpma.or.jp/opir/ 3 4 5 6 1 2 3 4 1 2 3 4 5 6 7 8 9 10 11 2013 2014
1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
1 13 4 15 1 2 13 7 6 1 2 3 4 4 1 2 3 4 2002 3 2005 7 8 548 15 6 27 14 189 4 5 5 6 3000 7 8 1 3 1 3 7,000 9 10 4 WHOWorld Health Report 2000 GDP 11 5 12 Managed Care 3 13 HMO 2000 HCA 14 15 16 17 18 Health
H27 28 4 1 11,353 45 14 10 120 27 90 26 78 323 401 27 11,120 D A BC 11,120 H27 33 H26 38 H27 35 40 126,154 129,125 130,000 150,000 5,961 11,996 6,000 15,000 688,684 708,924 700,000 750,000 1300 H28
政策研ニュースNo27
Views and Actions Points of View IMS World Review IMS Health Pfizer Johnson & Johnson Merck & Co Abbott Eli Lilly Amgen Wyeth Bristol Myers Squibb Schering Plough ForestBaxterMylanGlaxoSmithKline Novartis
account4-1.PDF
12 8 23 13 1 1 2 4 13 TEL 1 13 1 12 2 1 12 4 30 13 1 1 2 13 1 1 Office 13 1 1 13 1 1 1 12 2 1 12 4 30 99 3 office 3.1 4 office 426 147 85 3 6 12 2 1 13 1 31 office 5 2 3 4 5 6 7 8 12 2 1 12 4 30 11 8 1
EPSON
B K L & & & & & & & & L & & & & & & & K & & & & & L L L & & & K L L L & & L L L & & & & & & & & & & & & & & & & & & & & & & & & & & & L & K L K & & & & & & & L L & & L & & L L & & & & &
2012_05_GLK_cover.indd
c %& r Z \ W W n q & F % % & & % & & % % % & % & % & % & % & % & F F % % % & & & & % & A
2.8% 2.0% 2.4% 2.4% 0.4% 0.1% 0.3% 0.5% 3.8% 5.6% 25.6% 29.3% 64.6% 60.0% 1
2.8% 2.0% 2.4% 2.4% 0.4% 0.1% 0.3% 0.5% 3.8% 5.6% 25.6% 29.3% 64.6% 60.0% 1 16 24 21 20 20 23 10 11 9 10 3 3 3 2 3 1 3 4 6 8 2 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6 3 4 Q & A Q1 A1 Q2 A2 Q3 A3 7
Q&A最低資本金特例030131.PDF
& 1 2 2 3 2 2 3 2 2 3 10 11 10 90 12 13 14 15 16 17 18 19 20 2 2 3 21 2 2 3 22 23 24 25 20 10 26 27 28 10 8 1 29 30 10 8 2 31 32 2 2 3 33 10 8 3 10 11 2 34 10 8 3 10 12 2 35 36 20 10 37 38 39 40 41 42
™…
2/10 15 2010. No1362 1 1 216315 91430 Q A & 0.23% 1 1.4% 04-7120-2020 050-5540-2023 Q A & 1 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 1 2 3 4 5 6 7 8 9 10
bumon_pro.indd
q w e r t y u i o!0 !1!2!3 !4!5!6 !7!8!9 @0 @1 @2 @3 @4 @5 @6 @7 @8 @9 #0 #1 #2 #3 #4 #5 #6 #7 #8 #0 $0 $1 $2 $3 $4 $5 $6 $7 $8 $9 %0 %1 %2 %3 %4 %5 %6 %7 %8 %9 ^0 ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9 &0 &1 &2
2012_10_A_cover.indd
c %& r Z \ W n % & & % % & % & & % % % & % & % & & % & % %& % & % & % % % & & & W W W W A
‡o‡P†C‡P‡Q”R„û†^‡P†C‡P‡Q
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, Q & A ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Ｎｏ．１９
Views and Actions C Points of View boxwhisker plot EU ICH http wwwinfopmdagojp n n n n n n No n n n n n n pi pii pi pii pi pii n n n PKPD No HTBD HTBD CD LHRH RS HTBD EGFR AT DMARD HTBD HTBD TNFα α HMGCoA
B B 10 7 581 10 8 582 10 9 583 B B 10 11 585 10 12 586 B 10 10 584 B
10 1 575 10 12 586 B B 10 1 575 10 2 576 B B 10 4 578 10 5 579 10 3 577 B 10 6 580 B B B 10 7 581 10 8 582 10 9 583 B B 10 11 585 10 12 586 B 10 10 584 B 11 1 587 11 12 598 B B 11 1 587 11 2 588 11 3 589
（資料２）第７回資料その１（ヒアリング概要）
2 3 4 5 6 7 8 9 10 11 12 13 1 1 1 1 5 1 6 533 4 505 722 13 3325 475 1 2 3 13 10 31 1 1 1 (1) 1 (2) 2 (3) 3 (4) 4 5 5 6 7 8 8 8 9 11 11 12 13 14 15 16 19 (1) (2) (3) (1) (5 ) 1 (10 ) ( ) (2) 2 4 (3) 3 3,100
IT 180 181 1) 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 (a) (b) (c) (d) (e) (f) (a) (a) (b) 214 215 216 (a) (a) (a)
-------------------------- ----------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------
<4D F736F F D DEC8BC A95BD90AC E A982BA81698AB A B B4790DF90AB8EBE8AB FC89408A4F816A82CC93AE8CFC82C98AD682B782E9838C837C815B D
27 29 2 IT 1,234 1,447 2,130 1,200 3,043 4 3 75 75 70-74 -10 J00 J101 J110 J111 J118 J300 J302-304 J301 26,475,118 155,290,311 1,234 14,472,130 75,784,748 12,003,043 79,505,563 1 1.00% 0.62% 1.31% 9 12
, , ,210 9, ,
2006 5 642 7 2,671 35 732 1,727 602 489 386 74 373 533 305 1,210 9,786 2004 1,024 43.7 16.4 2004 978.6 40.2 2003 1 2006 5 1997 1998 1999 774 3,492 11 2,603 35 843 5,118 1,686 476 358 2000 738 3,534 11
a s d a s 30 d a s d 1229 10 1221 a s d 16181717 a s d 21 a s a 16 s 105 21 1620312020 1620312015 10500 05775 03675 01050 E { F ROE ROE 1,472,479 6,118,098
-1-
-1- -2 - 2000 1 1 5-3 - 21 10 2-4 - 5-5 - -6 - -7- -8 - 21 2000 21-9- IT in silico 10-10 - -11 - 20 21 1993 ICH - 12 - 2007 4 1 NIHThe National Institutes of Health2004 NIH NIH 2006 UK Clinical Research
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
Kobe University Repository : Kernel タイトル Title 著者 Author(s) 掲載誌 巻号 ページ Citation 刊行日 Issue date 資源タイプ Resource Type 版区分 Resource Version 権利 Rights DOI JaLCDOI URL グローバル市場における後発医薬品との競争 : 内資系大手製薬企業 4 社の事例研究
CEO 2017.10.30 Agenda Agenda ) 2000 2000 10 ~ ~ GLP: Good Laboratory Practice GCP: Good Clinical Practice GMP: Good Manufacturing Practice GPSP: Good Post-marketing Study 1 10,000 Practice GLP GMP GCP
CRC CRC CRC No F TEL : FAX : URL :
CRC CRC CRC No.18 2004 5 103-0023 3-4-1 5F TEL : 03-5200-2681 FAX : 03-5200-2684 E-mail : onozuka-opir@jpma.or.jp, asaka-opir@jpma.or.jp URL : http://www.jpma.or.jp/opir/ 1.... 1 2.... 2 2.1... 2 2.1.1...
untitled
259 2012 11 21 14 17 BOAZ 1985 9 6 4 20 10 1 8 5 5 2000 8 1 1 1 3 1 1966 45 3km 7 8 9 1971 1976 2 2000 5 1 3 350 3 1 10 34 3 40 25 40 20 40 60 100 20 401 10 4 3 5 1 40 1 7 1 19 34 510 1 1 10 10 1 CSR 10
障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
,
23 3 23 3 15 3.7 21 44,612 22 46,28 3.4 21 1,185 22 1,53 9,283 2 4,435 6 8.1 21 35,956 22 38,864 67.1 21 379 22 633 12,745 2.6 1.1 No.84 15 6 24 1 11 1 21 22 3.2 1.4 2291 22 4 2 5 15 1 6 5 1998 1999 11
Taro13-学習ノート表紙.PDF
10 11 12 13 13 14 15 18 22 27 30 32 A B C -1- -2- 1 2 A BC -3- -4- A B C -5- A B C -6- A B C -7- -8- 1-1 1-6 1-2 6-1 1-5 1-3 2-1 6-6 6-2 1-4 2-6 2-2 6-5 6-3 2-5 2-3 6-4 2-4 5-1 3-1 5-6 5-2 3-6 3-2 5-5
140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11
2 FRONTIER
Towada Chamber of Commerce & Industry 2 FRONTIER 2016. 8 3 FRONTIER 2016. 8 4 FRONTIER 2016. 8 5 FRONTIER 2016. 8 6 FRONTIER 2016. 8 FRONTIER 2016. 8 7 8 FRONTIER 2016. 8 9 FRONTIER 2016. 8 10 FRONTIER
University of Tsukuba2014
University of Tsukuba S c h o o l o f H e a l t h & P h y s i c a l E d u c a t i o n University of Tsukuba 2014 http://www.taiiku.tsukuba.ac.jp University of Tsukuba2014 School of Health & Physical Education,
June 11-13, 2010 Kyoto23
22 June 11-13, 2010 Kyoto23 24 June 11-13, 2010 Kyoto25 26 June 11-13, 2010 Kyoto27 28 June 11-13, 2010 Kyoto29 30 June 11-13, 2010 Kyoto31 32 June 11-13, 2010 Kyoto33 34 June 11-13, 2010 Kyoto35 36 June
2 / 29
Office 1 / 29 2 / 29 3 / 29 4 / 29 5 / 29 6 / 29 7 / 29 8 / 29 9 / 29 10 / 29 11 / 29 12 / 29 A 13 / 29 14 / 29 15 / 29 16 / 29 17 / 29 (R) 18 / 29 CD 19 / 29 20 / 29 21 / 29 22 / 29 23 / 29 24 / 29 25
PX-047A Series
B K L & L & A B C D E F A B A B C A B C A B A B A B C D E F G P BB H I y y & & K L L & & K L L L L & & & & L d L & & & & L L & & & L & & & & L & & & & & & & & L L L L L L & & & A B C D E F G
- 1 - - 2 - 320 421 928 1115 12 8 116 124 2 7 4 5 428 515 530 624 921 1115 1-3 - 100 250-4 - - 5 - - 6 - - 7 - - 8 - - 9 - & & - 11 - - 12 - GT GT - 13 - GT - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - -
6 6 6 6 1 2 3 4 5 6 7 8 R B1 B1 1 2 3 4 5 6 7 8 9
6 6 6 6 1 2 3 4 5 6 7 8 R B1 B1 1 2 3 4 5 6 7 8 9 B1F 7306730 96730 1F & 1069 2F & & 93069 3F 4F 1069 969 5F 6F 7F & & 8F 8F 9F 8306515 96.0534582130 1068 1066 4.0534582180 83069 0120-53-4305 0534542218
はじめにお読みください
START 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 @ 33 34 35 36 37 38 39 40 41 & @ 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 & 60 61 62 63 64 65 66 67 68
TK747取扱説明書
D D D D D D D E D D D D D D D D ; ; ; ; ; ; ; ; ; ; ; ; ; D D D D D D D D C C C C C ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; ;;;;; C C C C C C C C C C C C C C C C C D D D
3 JAS JAS JAS 4
1 2 3 JAS JAS JAS 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ph 102 106 K 31 32 13 3 15 79 33 34 35 36 37 20 6 H.22.3 http://www.caa.go.jp/foods/pdf/syokuhin19.pdf 38
2 / 43
Office 1 / 43 2 / 43 Access2003 3 / 43 Access2003 1 9 Access2003 4 / 43 5 / 43 6 / 43 7 / 43 8 / 43 9 / 43 10 / 43 11 / 43 12 / 43 13 / 43 14 / 43 15 / 43 16 / 43 17 / 43 18 / 43 19 / 43 20 / 43 21 / 43
1
1 2 1 4 4 6 7 9 9 10 10 17 19 21 25 26 29 32 34 37 39 41 42 44 45 48 53 62 63 3 4 5 6 7 7 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
第３回委員会（２月２０日）資料NO
ISO9001 ISO9001 E.Codman A.Donabedian Benefit, utility and risk A.Donabedian risk Output Output Output Adequacy Continuity / over time Efficacy (randomized controlled clinical trials) 7 Effectiveness
76
! # % & % & %& %& " $ 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 % & &! & $ & " & $ & # & ' 91 92 $ % $'%! %(% " %(% # &)% & 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 !$!$ "% "%
短信-1.PDF
ROE 3 A B C A B MA 14 12 2 1 4 2 2,245 ( 192 ) 448 ( 54 ) 396 ( 108 ) 181 459 ( 159 ) 107 51 309 341 244 388 661 2,279 5,590 90 740 15 3 31 14 3 31 14 9 30 % % % 2,239,549 3,315,424 1,075,875 2,901,303
†ı25”Y„o-PDF.ren
12,000 10,000 8,000 6,000 4,000 2,000 0 1998 1999 2000 2001 2002 2003 2004 1,200 1,000 800 600 400 200 0 1998 1999 2000 2001 2002 2003 2004 $ "! ''" '' ''$ ''% ''& '''! " ' & % $ "! ''" ' '$ '% '& ''!
10 10 10095 95 100 108
25491231 21 21 114 10 10 10095 95 100 108 10 10 2510 079685 10 100 109 20 2015 110 134 e [ 350 350 145 18 111 112 16 18 16 18 1816 18 20 48 25 20315 28 113 114 25 05 03 01 20 100150 Q & A Q A 18 16 Q &
取扱説明書[NE-202]
![取扱説明書[NE-202]](/thumbs/39/20478473.jpg "取扱説明書[NE-202]")
NE-202 13.3 m m 1 2 3 m 4 5 6 7 a a a 8 9 10 11 12 a a a a 13 14 15 16 17 2.4 FH 1/XX 4 18 19 20 21 22 23 24 25 26 27 1 2 3 4 5 6 m 7 h 8 r 9 a P b c d e f g h i j ud k l m n o 28 29 30 31 32 33 34 35
...a.T.X 04_PDF.p
2004 Sustainable Focus DAAM P19 P32 P42 P19 P41 P18 P16-17 P22 P23 4 21 KYOWA BIO-INNOVATOR 1. 2. 3. 4. 5. 6. 7. 8. 9. Kyowa Hakko Group s Sustainability Universe OUT CO2 SOx NOx IN OUT 2 MR IN OUT CONTENTS
,255 7, ,355 4,452 3,420 3,736 8,206 4, , ,992 6, ,646 4,
30 8 IT 28 1,260 3 1 11. 1101. 1102. 1103. 1 3 1,368.3 3 1,109.8 p.5,p.7 2 9,646 4,291 14.5% 10,p.11 3 3,521 8 p.13 45-49 40-44 50-54 019 5 3 1 2,891 3 6 1 3 95 1 1101 1102 1103 1101 1102 1103 1 6,255
5 10 10-1 - 5 20-2 - - 3 - - 4 - 22 6 30 10 12 22 7 8 1 30 4 30 1 22 7 14 10 12 20 22 7 21 1 30 3 30-5 - - 6 - - 7 - 11 9 9 14 10 9 15 7 9 10 NPO - 8 - - 15 - - 16 - - 17 - - 19 - - 20 - - 21 - - 22
